免疫检查点阻断通过扩增效应 CD8⁺ T 细胞克隆增强淋巴细胞清除性化疗诱导的抗肿瘤免疫
Immune Checkpoint Blockade Augments Lymphodepleting Chemotherapy-Induced Antitumor Immunity by Expanding Effector CD8+ T-cell Clones.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.
Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
黑色素瘤可出现骨软骨分化,但关于这一罕见亚型的报道很少。本文报告 8 例伴骨软骨分化的黑色素瘤,介绍其临床、病理和分子特征。病例与性别(男性 5 例、女性 3 例)或年龄(23–84 岁)无关联。病例包括原发黑色素瘤 6 例和远处转移 2 例;多数起源于皮肤(7/8),另 1 例来自黏膜。TIL(肿瘤浸润淋巴细胞)评分为 0–3 分(中位数 1),2/8 个病灶有炎症改变或既往创伤证据。新一代测序未发现肿瘤中存在复发性突变;检测到的突变更符合黑色素瘤,而非骨肉瘤样病变。多数肿瘤表达黑色素瘤标志物,包括 S100、HMB45、Melan-A、SOX10 和 MITF。成骨细胞标志物 SATB2 的染色从阴性到广泛阳性不等。研究显示,伴骨软骨分化的黑色素瘤临床表现具有异质性,且癌症相关基因中没有特征性复发突变。若骨软骨病变诊断不确定,可通过检测 BRAF、NRAS、NF1 等典型黑色素瘤基因突变,以及 S100、HMB45、Melan-A、SOX10 和 MITF 免疫组化阳性,支持黑色素瘤诊断。此类病变可能 SATB2 阳性,因此不能以 SATB2 阳性排除黑色素瘤。
Melanoma can present with osteocartilaginous differentiation, however few reports exist on this rare subtype.
We present eight cases of melanoma with osteocartilaginous differentiation to highlight its clinical, pathological and molecular features. The cases showed no association with gender (5 males and 3 females) or age (range 23-84 years). Cases included both primary melanomas and distant metastases (6 and 2, respectively), with the majority arising from cutaneous sites (7/8) and the remaining case from a mucosal site.
Tumour-infiltrating lymphocyte (TIL) score ranged from 0 to 3 (median 1), and 2/8 lesions had evidence of inflammatory changes or antecedent trauma. No recurrent mutations were found in the tumours by next generation sequencing, and the mutations observed were typical of melanoma rather than osteosarcomatous lesions. The majority of tumours stained positive for melanoma markers including S100, HMB45, Melan-A, SOX10 and MITF. Staining of the osteoblastic marker SATB2 varied from negative to widespread positive.
We demonstrate that melanomas with osteocartilaginous differentiation are heterogeneous in presentation and are not typified by a recurrent mutation in cancer associated genes. Where uncertainty exists in diagnosing an osteocartilaginous lesion, a diagnosis of melanoma can be supported by the presence of genomic mutations typical of melanoma such as BRAF, NRAS and NF1, and IHC staining positive for S100, HMB45, Melan-A, SOX10 and MITF. SATB2 may be positive in these lesions and thus should not be used to rule out melanoma.
MEMBER ACCOUNT
登录成功会直接打开下一页。